M. Hazzan, Obésité et transplantation rénale. Obésité, 2011.

A. Friedman, D. Miskulin, I. Rosenberg, and A. Levey, Demographics and trends in overweight and obesity in patients at time of kidney transplantation, American Journal of Kidney Diseases, vol.41, issue.2, pp.480-487, 2003.
DOI : 10.1053/ajkd.2003.50059

B. Stengel, C. Couchoud, C. Helmer, C. Loos-ayav, and M. Kessler, ??pid??miologie de??l'insuffisance r??nale chronique en??France, La Presse M??dicale, vol.36, issue.12
DOI : 10.1016/j.lpm.2007.04.039

F. M. Niels, W. Kok, I. P. Weimar, J. N. Alwayn, and . Ijzermans, The Current Practice of Live Donor Nephrectomy in Europe, Transplantation, vol.82, issue.7, 2006.

F. Philip, M. D. Halloran, and . D. Ph, Immunosuppressive Drugs for Kidney Transplantation, N Engl J Med, vol.351, pp.2715-2744, 2004.

S. Nicolaos, M. Burnel, C. Letailleur, P. Hiesse, A. Aubert et al., Relais oral de la ciclosporine A en transplantation rénale. journal de pharmacie clinique, 1998.

C. Augeraud, N. Viau, B. Hurault, T. De-ligny, J. Lobbedez et al., Conversion thérapeutique Sandimmum/Neoral : suivi en pratique clinique courante de 116 greffés rénaux, 1999.

C. Noel, D. Abramowicz, D. Durand, G. Mourad, P. Lang et al., Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients, Journal of the American Society of Nephrology, vol.20, issue.6, pp.1385-1392, 2009.
DOI : 10.1681/ASN.2008101037

B. J. Mihatschp, V. Nankivellq, J. C. Nickeleitr, P. Papadimitriouh, H. Randhawas et al., Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions, American Journal of Transplantation, vol.8, pp.753-760, 2008.

S. Bourry, «Pneumocystose chez le transplanté rénal : quels patients et quel mode de contaminantion?» octobre, 2011.

A. L. Basdevant, obésité : origines et conséquences d'une épidémie, Comptes rendus Biologies, vol.329, issue.8, 2006.

A. Basdevant, Obésité : épidémiologie et santé publique Annales d'endocrinologie, 2000.

B. Guy-grand, De l'obésité aux obésités : des concepts aux pratiques. Annales d'endocrinologie, pp.5-7, 2003.

M. Charles, Obésité : que nous dit l'épidémiologie? Cahiers de Nutrition et de Diététique, 2011.

D. Ducloux, A. Kazory, D. Simula-faivre, and J. Chalopin, One-Year Post-Transplant Weight Gain is a Risk Factor for Graft Loss, American Journal of Transplantation, vol.52, issue.10 Suppl., pp.2922-2930, 2005.
DOI : 10.1111/j.1600-6143.2005.01104.x

J. Clunk, C. Lin, and J. Curtis, Variables affecting weight gain in renal transplant recipients, American Journal of Kidney Diseases, vol.38, issue.2, pp.349-53, 2001.
DOI : 10.1053/ajkd.2001.26100

K. Potluri and S. Hou, Obesity in Kidney Transplant Recipients and Candidates, American Journal of Kidney Diseases, vol.56, issue.1, pp.143-56, 2010.
DOI : 10.1053/j.ajkd.2010.01.017

O. Imhoff, S. Caillard, and B. Moulin, Le receveur limite existe-t-il encore des freins à l'inscription des patients sur liste d'attente de transplantation rénale? Néphrologie et thérapeutique, 2007.

. Boulamery-velly and B. Simon, Particularités pharmacocinétiques chez le patient obèse. Réanimation, p.15, 2006.

M. Ladrière, Y. Foucher, C. Legendre, . Kamar, . Garrigue et al., The Western Europe Cohort Of Kidney Transplanted Recipients -The DIVAT Network

. Yee, . Lennon, . Gmur, . Cheney, and D. Oeser, Effect of obesity on cyclosporine disposition. Transplantation, p.45, 1988.

. Flechner, . Kolbeinsson, . Lum, . Tam, and . Moran, The effect of obesity on cyclosporine pharmacokinetics in uremic patients. Transplantation proceedings, 1989.

. Flechner, . Kolbeinsson, and L. Tam, The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation, p.47, 1989.

D. Colombo and C. Egan, Bioavailability of Sandimmun?? versus Sandimmun Neoral??: A Meta-Analysis of Published Studies, International Journal of Immunopathology and Pharmacology, vol.28, issue.64, pp.1177-83, 2010.
DOI : 10.1093/ndt/16.6.1256

L. Frimat, E. Cassuto-viguierb, B. Charpentierc, C. Noel, F. Provot et al., Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The 'Reference' Study, American Journal of Transplantation, vol.15, issue.11, pp.2725-2734, 2006.
DOI : 10.1046/j.1600-6143.2005.00779.x

URL : https://hal.archives-ouvertes.fr/inserm-00473412

M. Hazzan, M. Labalette, M. C. Copin, F. Glowacki, F. Provot et al., Predictive Factors of Acute Rejection after Early Cyclosporine Withdrawal in Renal Transplant Recipients Who Receive Mycophenolate Mofetil: Results from a Prospective, Randomized Trial, Journal of the American Society of Nephrology, vol.16, issue.8
DOI : 10.1681/ASN.2005030312

M. Giral, Y. Foucher, G. Karam, Y. Labrune, M. Kessler et al., Kidney and Recipient Weight Incompatibility Reduces Long-Term Graft Survival, Journal of the American Society of Nephrology, vol.21, issue.6, pp.1022-1029, 2010.
DOI : 10.1681/ASN.2009121296

URL : http://jasn.asnjournals.org/content/21/6/1022.full.pdf

D. Song, J. Zhao, and L. Zhang, TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment, Journal of Clinical Pharmacy and Therapeutics, vol.67, issue.6, pp.627-635, 2006.
DOI : 10.1097/01.ftd.0000164393.09402.c9

S. Vannaprasaht, S. Angsuthum, Y. Avihingsanon, D. Sirivongs, C. Pongskul et al., Impact of the heterozygous TPMT1/3C genotype on azathioprine-induced myelosuppression in kidney transplant recipients in Thailand, Clinical Therapeutics, vol.31, issue.7, pp.1524-1533, 2009.
DOI : 10.1016/j.clinthera.2009.07.008

C. Couet, D. Jacobi, and F. Maillot, Obésité de l'adulte. Nutrition clinique pratique, pp.167-182, 2011.

A. Didier and C. , Asthme, alimentation et ob??sit??, Revue Fran??aise d'Allergologie, vol.51, issue.3, pp.126-129, 2011.
DOI : 10.1016/j.reval.2011.01.020

G. Cheymol, Clinical Pharmacokinetics of Drugs in Obesity, Clinical Pharmacokinetics, vol.25, issue.2, pp.103-117, 1993.
DOI : 10.2165/00003088-199325020-00003

B. Green and S. Duffull, What is the best size descriptor to use for pharmacokinetic studies in the obese?, British Journal of Clinical Pharmacology, vol.42, issue.2, pp.119-152, 2004.
DOI : 10.1001/archneur.1985.04060050066010

J. Aalten, M. Christiaans, and H. De-fijter, The influence of obesity on short- and long-term graft and patient survival after renal transplantation, Transplant International, vol.11, issue.11, pp.901-908, 2006.
DOI : 10.1097/01.TP.0000120949.86038.62

F. Vincenti, B. Charpentier, and Y. Vanrenterghem, A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study), American Journal of Transplantation, vol.103, issue.3, pp.535-546, 2010.
DOI : 10.1111/j.1600-6143.2007.02057.x

. Dantal, Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial, Transplant International, vol.349, issue.Suppl. 9, pp.1084-1093, 2010.
DOI : 10.1164/ajrccm.163.2.2006093

. Lebranchu, Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study, American Journal of Transplantation, vol.78, issue.5, pp.1115-1123, 2009.
DOI : 10.1111/j.1600-6143.2009.02615.x

. Levey, National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Annals of Internal Medicine, vol.139, issue.2, pp.137-147, 2003.
DOI : 10.7326/0003-4819-139-2-200307150-00013

P. Eggers, P. Van-lente, P. Greene, J. Coresh, . Md et al., Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate, Annals of Internal Medicine, vol.150, issue.9, pp.604-613, 2009.

D. Dlplome, . Pharmacie, and . Par, BAL Claire Su jet : Uti lisat ion de la ciclosporine chez le transplanté réna l obèse: l'attitude actue lle est-elle adaptée?